Alessia Garufi

Via Elio Chianesi 53
Rome, 00144, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Pyrazolone-Based Zn(II) Complexes Display Antitumor Effects in Mutant p53-Carrying Cancer Cells.

Pyrazolone-Based Zn(II) Complexes Display Antitumor Effects in Mutant p53-Carrying Cancer Cells.

Journal: Journal of medicinal chemistry

Published: September 02, 2024

HIPK2 in Colon Cancer: A Potential Biomarker for Tumor Progression and Response to Therapies.

HIPK2 in Colon Cancer: A Potential Biomarker for Tumor Progression and Response to Therapies.

Journal: International journal of molecular sciences

Published: June 24, 2024

Recent Advances on Mutant p53: Unveiling Novel Oncogenic Roles, Degradation Pathways, and Therapeutic Interventions.

Recent Advances on Mutant p53: Unveiling Novel Oncogenic Roles, Degradation Pathways, and Therapeutic Interventions.

Journal: Biomolecules

Published: May 07, 2024

New Copper-Based Metallodrugs with Anti-Invasive Capacity.

New Copper-Based Metallodrugs with Anti-Invasive Capacity.

Journal: Biomolecules

Published: September 03, 2023

NRF2 activation in BON‑1 neuroendocrine cancer cells reduces the cytotoxic effects of a novel Ruthenium(II)‑curcumin compound: A pilot study.

NRF2 activation in BON‑1 neuroendocrine cancer cells reduces the cytotoxic effects of a novel Ruthenium(II)‑curcumin compound: A pilot study.

Journal: Oncology reports

Published: July 31, 2023

The Sweet Side of HIPK2.

The Sweet Side of HIPK2.

Journal: Cancers

Published: March 27, 2023

NRF2 and Bip Interconnection Mediates Resistance to the Organometallic Ruthenium-Cymene Bisdemethoxycurcumin Complex Cytotoxicity in Colon Cancer Cells.

NRF2 and Bip Interconnection Mediates Resistance to the Organometallic Ruthenium-Cymene Bisdemethoxycurcumin Complex Cytotoxicity in Colon Cancer Cells.

Journal: Biomedicines

Published: January 23, 2023

HIPK2 in Angiogenesis: A Promising Biomarker in Cancer Progression and in Angiogenic Diseases.

HIPK2 in Angiogenesis: A Promising Biomarker in Cancer Progression and in Angiogenic Diseases.

Journal: Cancers

Published: January 11, 2023

HIPK2 as a Novel Regulator of Fibrosis.

HIPK2 as a Novel Regulator of Fibrosis.

Journal: Cancers

Published: December 23, 2022

The Impact of NRF2 Inhibition on Drug-Induced Colon Cancer Cell Death and p53 Activity: A Pilot Study.

The Impact of NRF2 Inhibition on Drug-Induced Colon Cancer Cell Death and p53 Activity: A Pilot Study.

Journal: Biomolecules

Published: February 17, 2022

P62/SQSTM1/Keap1/NRF2 Axis Reduces Cancer Cells Death-Sensitivity in Response to Zn(II)-Curcumin Complex.

P62/SQSTM1/Keap1/NRF2 Axis Reduces Cancer Cells Death-Sensitivity in Response to Zn(II)-Curcumin Complex.

Journal: Biomolecules

Published: February 09, 2021

A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status.

A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status.

Journal: Journal of experimental & clinical cancer research : CR

Published: June 04, 2020

Showing 1-12 of 36

Last Updated: 09/26/2026